Also trades as: SUVENPHAR.NS (NSE) · $vol 3M
SUVENPHAR.BO BSE
Suven Pharmaceuticals Limited
1W: +0.3%
1M: -4.4%
3M: -13.6%
1Y: +61.1%
3Y: +71.2%
5Y: +626.3%
₹1,075.30
Last traded 2025-06-10 — delisted
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$2.9B
-19.6% ▼
5Y CAGR: -7.1%
Capital Expenditures
$1.6B
-200.7% ▼
5Y CAGR: +9.4%
Free Cash Flow
$1.3B
-56.8% ▼
5Y CAGR: -16.0%
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$384M
+318.4% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $4.7B | $6.7B | $5.6B | $3.0B | $3.4B |
| Depreciation & Amort. | $312M | $383M | $465M | $546M | $775M |
| Stock-Based Comp. | $0 | $0 | $0 | $20M | $149M |
| Change in Working Capital | -$113M | -$1.9B | $56M | $474M | -$321M |
| Other Non-Cash Items | -$1.0B | -$1.8B | -$1.6B | -$458M | -$1.2B |
| Operating Cash Flow | $3.8B | $3.3B | $4.5B | $3.6B | $2.9B |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.1B | -$752M | -$2.9B | -$518M | -$1.6B |
| Acquisitions (Net) | $336K | $6K | $720K | $0 | -$7.3B |
| Investment Purchases | -$2.0B | -$3.0B | -$44K | -$3.1B | -$3.5B |
| Investment Sales | -$336K | $2.4B | $845M | $11M | $9.8B |
| Other Investing | $309K | -$48M | $64M | $20M | $2M |
| Investing Cash Flow | -$3.1B | -$1.4B | -$1.9B | -$3.6B | -$2.6B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$424M | -$482M | -$264M | -$64M | $228M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$255M | -$1.0B | -$2.0B | $0 | $0 |
| Other Financing | -$78M | -$64M | -$119M | -$75M | -$195M |
| Financing Cash Flow | -$766M | -$1.6B | -$2.4B | -$138M | $33M |
| Net Change in Cash | -$45M | $374M | $202M | -$176M | $384M |
| Cash End of Period | $72M | $446M | $648M | $472M | $856M |
| Free Cash Flow | $2.7B | $2.5B | $1.7B | $3.1B | $1.3B |